Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential. Inhibrx Biosciences, Inc.
Inhibrx Biosciences Inc. (INBX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 1,297,763 | $122,963,044 | -11% | 1.85% |
| 2. | Viking Global Andreas Halvorsen | 1,123,929 | $106,492,273 | -22% | 0.3% |
| 3. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 697,586 | $66,096,272 | +174% | 0.24% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 400,892 | $37,984,517 | +5% | 0.12% |
| 5. | Partner Fund Management Christopher Medlock James | 308,385 | $29,219,479 | +1% | 2.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $113.52 | 5,000 | $567,580.00 | 424,360 | 2026-09-08 | Filing | |
| $114.65 | 2,500 | $286,617.25 | 227,064 | 2026-09-08 | Filing | |
| $112.28 | 9,681 | $1,087,001.07 | 730,548 | 2026-09-08 | Filing | |
| $111.88 | 1,219 | $136,382.33 | 720,867 | 2026-09-08 | Filing | |
| $108.24 | 500 | $54,117.50 | 719,648 | 2026-09-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $115.80 | 500 | $57,897.50 | 9,000 | 2026-09-09 | Filing | |
| $115.14 | 500 | $57,570.00 | 9,500 | 2026-09-08 | Filing | |
| $32.25 | 25,042 | $807,604.50 | 102,864 | 2025-10-07 | Filing | |
| $32.25 | 16,315 | $526,158.75 | 67,018 | 2025-10-07 | Filing | |
| $32.25 | 308,643 | $9,953,736.75 | 1,267,823 | 2025-10-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,308,051 | $123,937,898 | 0.01% | |
| 2. | 1,157,926 | $109,713,489 | 20.54% | |
| 3. | 870,551 | $82,484,676 | 0.07% | |
| 4. | 841,141 | $79,698,110 | 0.01% | |
| 5. | 825,972 | $78,260,825 | 0% |
News See All
15 Best Small Cap Stocks to Buy for 10x Potential
In this article, we will look at the 15 Best Small Cap Stocks to Buy for 10x Potential.
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the best emerging technology stocks to invest in.
12 Best Emerging Technology Stocks to Invest In
On December 24, Kevin Simpson of Capital Wealth Planning joined 'Closing Bell' on CNBC to talk about AI tailwinds and the diverging tech picture.
Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer
Inhibrx Biosciences Inc. (NASDAQ:INBX) is one of the most profitable new stocks to buy now.
10 Most Profitable New Stocks to Buy Now
Earlier on July 1, Ralph Schlosstein, Evercore's chairman emeritus and BlackRock's co-founder, joined 'Closing Bell Overtime' on CNBC to talk about his outlook for markets heading into H2 2025.
12 Best High Risk High Reward Stocks To Buy Now
In this piece, we will take a look at the 12 best high risk high reward stocks to buy now. Investing is a risky endeavor, as is anything that involves the future.
Should You Hold Inhibrx (INBX)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
Hedge Fund Resource Center